Dimitrios Skaltsas is the CEO and Co-Founder of Intelligencia AI, where he drives business and investment growth while leading a multidisciplinary global team. Since its founding in 2017, Intelligencia AI has leveraged proprietary data, biomedical expertise, and AI to address major pharmaceutical challenges, including lengthy drug development timelines, high costs, and suboptimal ROI. Its AI-powered solutions deliver precise, unbiased assessments of a drug’s probability of success, supporting informed decision-making and risk mitigation. In 2024, the company received a U.S. patent for its probability-of-success assessments and earned its first spots on the Inc. Regional (Northeast) and Inc. 5000 lists. The Healthcare Technology Report also recognized Intelligencia AI among the Top 100 Healthcare Technology Companies. Following its Series A funding in 2021, the company was highlighted by Forbes as a Top AI Company to Watch. During this time, Dimitrios was instrumental in establishing a strategic partnership with ZS, a global professional services firm. He holds an MBA from INSEAD and law degrees from University College London (UCL) and the University of Athens, bringing over a decade of leadership experience in the healthcare and life sciences sectors.